Patent: 9,534,058
✉ Email this page to a colleague
Summary for Patent: 9,534,058
Title: | Anti-CD324 monoclonal antibodies and uses thereof |
Abstract: | Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. |
Inventor(s): | Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) |
Assignee: | ABBVIE STEMCENTRX LLC (North Chicago, IL) |
Application Number: | 14/377,343 |
Patent Claims: | see list of patent claims |
Details for Patent 9,534,058
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-02-08 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2032-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-02-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |